Pulmonary Hypertension – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)

Pulmonary hypertension (PH) is a high-burden condition with significant unmet needs across the major markets. Despite its small patient pool, the commercial potential for PH therapies is substantial, driven by premium pricing and polypharmacy. Current treatment dynamics are shaped by phosphodiesterase-5 inhibitors (PDE-5) and endothelin receptor antagonists (ERAs). Late-phase developments, including Gossamer Bio’s seralutinib and United Therapeutics’ ralinepag, signal continued innovation in expanding treatment options. Commercial interest in PH remains strong, driven by the need for more effective, disease-modifying therapies and the absence of approved options for underserved patient populations. Our forecast model includes pulmonary arterial hypertension (PAH), PH related to interstitial lung disease (PH–ILD), and inoperable chronic thromboembolic pulmonary hypertension (CTEPH) patients.

Questions answered

• How is the treatment landscape for PH evolving across the major markets?
• What are KOLs’ views on Merck & Co.’s sotatercept and its unique nonvasodilatory mechanism of action, and how has its launch influenced their prescribing decision?
• How will late-phase emerging therapies, such as ralinepag and seralutinib, shape the PH market and competitive positioning?
• How have generic launches impacted prescribing patterns and brand performance? How will these formulations affect the uptake of emerging therapies?

Geography: United States, EU5, Japan

Primary research: Country-specific interviews with thought-leading cardiologists and pulmonologists; survey data collected for this and other Clarivate research

Epidemiology: Diagnosed prevalence of PH by country, cause of the disease, and drug-treated rates.

Forecast: 10-year, annualized, drug-level sales and patient share of key PH therapies through 2035, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.